Literature DB >> 19017617

Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide.

L De Petrocellis1, R Deva, F Mainieri, M Schaefer, T Bisogno, R Ciccoli, A Ligresti, K Hill, S Nigam, G Appendino, V Di Marzo.   

Abstract

The fungal pathogen Candida albicans transforms arachidonic acid (AA) into 3-hydroxyarachidonic acid [3R-HETE], and we investigated if its nonpathogenic and 3R-HETE-producing close relative, Dipodascopsis uninucleata, could similarly transform the endocannabinoid/endovanilloid anandamide into 3-hydroxyanandamide (3-HAEA). We found that D. uninucleata converts anandamide into 3-HAEA, and we therefore developed an enantiodivergent synthesis for this compound to study its pharmacological activity. Both enantiomers of 3-HAEA were as active as anandamide at elevating intracellular Ca2+ via TRPV1 receptors overexpressed in HEK-293 cells, while a approximately 70-90-fold and approximately 45-60-fold lower affinity at cannabinoid CB1 and CB2 receptors was instead observed. Patch clamp recordings showed that 3R-HAEA activates a TRPV1-like current in TRPV1-expressing HEK-293 cells. Thus, 3R-HETE-producing yeasts might convert anandamide released by host cells at the site of infection into 3R-HAEA, and this event might contribute to the inflammatory and algogenous responses associated to fungal diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017617      PMCID: PMC2656659          DOI: 10.1194/jlr.M800337-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

1.  Recent developments in cyclooxygenase inhibition.

Authors:  Lawrence J Marnett
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

2.  The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism.

Authors:  L De Petrocellis; T Bisogno; M Maccarrone; J B Davis; A Finazzi-Agro; V Di Marzo
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

3.  Involvement of aspirin-sensitive oxylipins in vulvovaginal candidiasis.

Authors:  R Deva; R Ciccoli; L Kock; S Nigam
Journal:  FEMS Microbiol Lett       Date:  2001-04-20       Impact factor: 2.742

4.  The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase.

Authors:  L De Petrocellis; S Harrison; T Bisogno; M Tognetto; I Brandi; G D Smith; C Creminon; J B Davis; P Geppetti; V Di Marzo
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

5.  A simple method for the preparation of (5Z,8Z,11Z,14Z)-16-hydroxyeicosa-5,8,11,14-tetraenoic acid enantiomers and the corresponding 14,15-dehydro analogues: role of the 16-hydroxy group for the lipoxygenase reaction.

Authors:  Igor V Ivanov; Stepan G Romanov; Nataliya V Groza; Santosh Nigam; Hartmut Kuhn; Galina I Myagkova
Journal:  Bioorg Med Chem       Date:  2002-07       Impact factor: 3.641

Review 6.  Possible mechanisms of cannabinoid-induced antinociception in the spinal cord.

Authors:  V Morisset; J Ahluwalia; I Nagy; L Urban
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

7.  The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1).

Authors:  D Smart; M J Gunthorpe; J C Jerman; S Nasir; J Gray; A I Muir; J K Chambers; A D Randall; J B Davis
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

8.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity.

Authors:  L De Petrocellis; T Bisogno; J B Davis; R G Pertwee; V Di Marzo
Journal:  FEBS Lett       Date:  2000-10-13       Impact factor: 4.124

9.  N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor.

Authors:  Giovanni Appendino; Alberto Minassi; Aniello Schiano Morello; Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

Review 10.  TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications.

Authors:  Katarzyna Starowicz; Luigia Cristino; Vincenzo Di Marzo
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more
  4 in total

Review 1.  "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.

Authors:  Fabiana Piscitelli; Vincenzo Di Marzo
Journal:  ACS Chem Neurosci       Date:  2012-02-27       Impact factor: 4.418

Review 2.  Skin Immunity to Candida albicans.

Authors:  Sakeen W Kashem; Daniel H Kaplan
Journal:  Trends Immunol       Date:  2016-05-10       Impact factor: 16.687

Review 3.  Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

Authors:  Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-22       Impact factor: 4.147

4.  A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons.

Authors:  Luciano De Petrocellis; Aniello Schiano Moriello; Roberta Imperatore; Luigia Cristino; Katarzyna Starowicz; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.